Your session is about to expire
← Back to Search
Neurostimulation for Paroxysmal Sympathetic Hyperactivity
Study Summary
This trial will test whether a non-invasive device that sends electrical signals to the ear can help treat symptoms of Paroxysmal Sympathetic Hyperactivity, which include a fast heart rate, high blood pressure, and rapid breathing.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are any slots still available for participants in this experiment?
"By consulting the information on clinicaltrials.gov, we can confirm that this medical trial is still actively recruiting patients. It was first published on September 22nd 2022 and has since been amended on the 26th of the same month."
Is the age threshold for enrollment in this trial restricted to under 35 years?
"In order to be included in this medical experiment, the minimum participant age is 2 years old and the maximum allowable age is 17."
May I join this research trial?
"This study is currently sourcing 20 volunteers between the ages 2 and 17 with paroxysmal sympathetic hyperactivity. The eligibility requirements are: Children afflicted by ASBI-induced PSH, a moderate severity score (greater than 6) on their PSH rating scale, and Glasgow Coma Scale lower than 15."
What are the expected benefits of this research?
"As the primary outcome of this trial, a cohort of 2-17 year olds with acute severe brain injury (ASBI) and paroxysmal sympathetic hyperactivity (PSH) will be monitored for up to 192 hours while using percutaneous electrical nerve field stimulation (PENFS). Secondary results include an assessment in maintenance and rescue medication use, heart rate variability's standard deviation of NN intervals (SDNN), as well as total power parameter. All data collected over 12 hour periods before and after PENFS therapy will then be compared against historical cohorts from January 2018 - August 2021 via spearman correlation coefficient analysis."
How many participants are being included in this clinical investigation?
"Affirmative. The clinical trial's data hosted on the website of clinicaltrials.gov attests to this study's current recruitment phase, which commenced on September 22nd 2022 and was updated lastly on September 26th 2022. A total of 20 individuals are to be enrolled from a single medical site for participation in the research experiment."
Share this study with friends
Copy Link
Messenger